Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
Author:
Nazzareno Cannella,Veronica Lunerti,Qianwei Shen,Hongwu Li,Federica Benvenuti,Laura Soverchia,Rajesh Narendran,Friedbert Weiss,Roberto Ciccocioppo
Publication:
Neuropharmacology
© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.